Renal function impairment cancer patients

Memoli B, De Nicola L, Libetta C, Scialo A, Pacchiano G, Romano P, Palmieri G, Morabito A, Lauria R, Conte G, et al. lnterleukin-2-induced renal dysfunction in cancer patients is reversed by low-dose dopamine infusion, Am J Kidney Dis 1995, 26 27-33 Palmieri G, Morabito A, Lauria R, Montesarchio V, Matano E, Memoli B, Libetta C, Rea A, Merola C, Correale P, et al. Low-dose dopamine induces early recovery of recombinant interleukin-2-impaired renal function, EurJ Cancer 1993,29A 1119-1122... 

Massari C, Brienza S, Rotarski M, et al. Pharmacokinetics of oxaliplatin in patients with normal versus impaired renal function. Cancer Chemother. Pharmacol, 2000, 45, 157-164. 

Hepatic and renal function. Patients with advanced cancer may have impaired liver function due to the presence of liver metastases. In this case drug doses may need to be adjusted. In the case of the FOLFOX regimen, 5-fluorouracil dose may need to be reduced if the impairment is moderate or severe. Mrs KT s baseline liver function tests indicate a normal liver function, but these parameters should be monitored carefully throughout treatment. Reduced renal function may also necessitate a decrease in drug dosage. In the case of the FOLFOX regimen, oxaliplatin is contraindicated in patients with severe renal impairment (creatinine clearance <30 mL/min). 

Camaggi CM, Strocchi E, Tamassia V, Martoni A, Giovannini M, Lafelice G, Canova N, Marraro D, Martini A, Pannuti F. Pharmacokinetic studies of 4 -epi-doxorubicin in cancer patients with normal and impaired renal function and with hepatic metastases. Cancer Treat Rep 1982 66(10) 1819-24. 

Ocular effects, including optic neuritis, papilledema, and retrobulbar neuritis, are uncommon adverse effects of cisplatin-containing cancer chemotherapy. The risk of retinal toxicity is restricted to high-dose cisplatin therapy (for example 200 mg/m over 5 days) and can result in blurred vision and altered color perception, which can persist for several months. In contrast to cisplatin, carbo-platin is seldom involved in drug-induced visual disturbances. In two cases there was a relation between the administration of carboplatin (800-1200 mg/m ) and the occurrence of chnical cortical blindness (122). However, both patients had impaired renal function before the start of therapy with carboplatin. 

Harland SJ, Newell DR, SiddikZH, Chadwick R,Calvert AH, Harrap KR. Pharmacokinetics of cis-diammine-1,1-cyclobutane dicarboxylate platinum[ll] in patients with normal and impaired renal function. Cancer Res. 1984 Apr 44[4] 1693-7 Koeller JM,Trump DE,Tutsch KD, Earhart RH, DavisTE,Tormey DC. Phase I clinical trial and pharmacokinetics of carboplatin [NSC 241240] by single monthly 30-minute infusion. Cancer. 1986 Jan 15 57[2] 222-5... 

Egorin MJ,Van Echo DA, Tipping SJ, Olman EA,Whitacre MY, Thompson BW, Aisner J. Pharmacokinetics and dosage reduction of cis-diammine[1,1-cyclobutanedicarboxylato]platinumin patients with impaired renal function. Cancer Res. 1984 Nov 44[11] 5432-8... 

Berenson JR, Rosen L, Vescio R, Lau FIS, Woo M, SloufI A, Kowalski MO, Knight RD, Seaman JJ. Pharmacokinetics of pamidronate disodium in patients with cancer with normal or impaired renal function. J Clin Pharmacol 1997 37 285-290. 

---